Inj vancomycin and ceftaz given both at the same time jst after one
Reading File
Searching the Web
vancomycin ceftazidime compatibility IV Y-site precipitation flush
Here is the full clinical picture on vancomycin + ceftazidime co-administration:
Vancomycin + Ceftazidime - Compatibility Issue
The Core Problem: They Are INCOMPATIBLE
Vancomycin and ceftazidime are physically incompatible when they come into direct contact. This is well-documented:
- Pfizer's own vancomycin labeling states: "Mixtures of solutions of vancomycin and beta-lactam antibiotics have been shown to be physically incompatible."
- Wazny & Blake (2002) specifically documented incompatibility of vancomycin + ceftazidime for intraperitoneal use.
- Cairns & Robertson (1987) published on "Incompatibility of ceftazidime and vancomycin" in the Pharmaceutical Journal.
Looking at the Y-site compatibility chart from Vancouver Coastal Health: Vancomycin + Ceftazidime = "I" (Incompatible).
What Happens When Given Together Without Flushing?
| Risk | Detail |
|---|---|
| Precipitation | A white/cloudy precipitate forms in the IV line or catheter |
| Particulate embolism | Precipitated particles can enter the bloodstream |
| Drug loss | Both drug concentrations drop - you lose therapeutic efficacy |
| Line occlusion | The catheter/tubing can become blocked |
What Should Have Been Done (Correct Practice)
- Give each drug through a separate IV line/lumen (preferred) - ideal if patient has a multi-lumen central line
- If only one line available: flush with at least 10-20 mL of Normal Saline (0.9% NaCl) between the two drugs - do NOT run them back-to-back without this flush
- Dilute vancomycin to 5 mg/mL or less to reduce precipitation risk
- Never mix them in the same bag or syringe
What to Do Now (If Already Given Without Flushing)
- Inspect the IV line - look for cloudiness, white precipitate, or discoloration
- Do not re-use that line until it has been flushed or replaced
- Assess the patient - check for signs of infusion reaction, line occlusion, or unexplained clinical deterioration
- Consider pharmacist review of both drug levels/efficacy if doses may have been lost to precipitation
- If the patient has a central line and there is concern about catheter precipitation, line replacement may be needed
Special Case: Intravitreal Injection
Pfizer's labeling also notes that precipitation has been reported after intravitreal injection of vancomycin + ceftazidime (different syringes, different needles) for endophthalmitis - so incompatibility is not just a mixing issue but a tissue-contact issue too.
Bottom line: Always flush with NS between these two drugs if using the same line. The safest approach is a separate IV access point for each. This is a well-known incompatibility pair that every nurse/pharmacist/clinician should be aware of.
But When will give this both injection seperately
Finding Sources
Searching the Web
vancomycin ceftazidime combination indications clinical use when both prescribed
Here is a clear breakdown of when both vancomycin AND ceftazidime are given together (separately):
Why Give Both Together?
The logic is simple - they cover different organisms:
| Drug | Covers |
|---|---|
| Vancomycin | Gram-POSITIVE bacteria - especially MRSA, MRSE, resistant Enterococci |
| Ceftazidime | Gram-NEGATIVE bacteria - especially Pseudomonas aeruginosa, Klebsiella, E. coli, Enterobacter |
Together = broad-spectrum empirical coverage of both Gram+ and Gram- organisms when you cannot wait for culture results.
Clinical Situations Where Both Are Given Together
1. Febrile Neutropenia / Immunocompromised Patients
- Cancer patients on chemotherapy, bone marrow transplant patients
- High risk of both MRSA and Pseudomonas
- Start both empirically while waiting for blood cultures
2. Hospital-Acquired / Ventilator-Associated Pneumonia (HAP/VAP)
- Gram-negatives (especially Pseudomonas) + MRSA risk in ICU
- Ceftazidime covers Pseudomonas; vancomycin covers MRSA
3. Meningitis / CNS Infections (Nosocomial)
- Post-neurosurgery, VP shunt infection, epidural abscess
- Need Pseudomonas coverage (ceftazidime) + MRSA coverage (vancomycin)
- Harrison's specifically states: empirical therapy should include a 3rd-generation cephalosporin + vancomycin
4. Epidural Abscess / Spinal Osteomyelitis
- Rosen's Emergency Medicine recommends vancomycin for MRSA coverage plus a Gram-negative cover
5. Brain Abscess (Post-surgical / Nosocomial)
- Harrison's: empirical therapy includes combination of cephalosporin (ceftazidime if Pseudomonas risk) + vancomycin
6. Sepsis / Septic Shock (Unknown Source)
- When patient is critically ill and source unknown
- Especially in ICU, dialysis patients, IV drug users
- Cover all possibilities empirically
7. Peritoneal Dialysis (PD) Peritonitis
- International guidelines recommend vancomycin (Gram+) + ceftazidime (Gram-) for empirical PD peritonitis treatment
- This is one of the most classic textbook indications for this combination
8. Endophthalmitis
- Intravitreal injection of both for post-surgical eye infection
- (Though precipitation risk is documented even with separate syringes - as noted previously)
9. Cystic Fibrosis Exacerbations
- Pseudomonas is a dominant organism; MRSA can co-exist
Summary Table
| Condition | Why Vancomycin? | Why Ceftazidime? |
|---|---|---|
| Febrile neutropenia | MRSA/resistant Gram+ | Pseudomonas |
| HAP/VAP in ICU | MRSA | Pseudomonas/GNR |
| Nosocomial meningitis | MRSA, resistant Staph | Pseudomonas, GNR |
| PD peritonitis | Gram+ cocci | Gram- rods |
| Epidural/brain abscess (post-op) | MRSA | Pseudomonas |
| Sepsis (unknown source, ICU) | MRSA coverage | GNR/Pseudomonas |
Key Point to Remember
Both drugs must be given through separate IV lines, or with a proper NS flush (10-20 mL) in between when using the same line. They target completely different bacteria, which is why the combination is clinically valuable - but they must never physically contact each other in the line.
What are the dosing schedules for vancomycin and ceftazidime in these conditions?
Finding Sources
Finding Sources
Reading File
Reading File
Finding Sources
Finding Sources
Finding Sources
Reading File
Finding Sources
Here is a complete, condition-by-condition dosing reference for both drugs:
Vancomycin + Ceftazidime - Dosing Schedules by Condition
VANCOMYCIN - Standard Dosing
Adults (Normal Renal Function)
| Parameter | Dose |
|---|---|
| Standard dose | 15-20 mg/kg IV q8-12h |
| Serious infections (empirical) | 25-30 mg/kg IV loading dose, then 15-20 mg/kg q8-12h |
| Daily range | 30-45 mg/kg/day in 2-3 divided doses |
| Infusion rate | Never exceed 1 g/hour (to avoid Red Man Syndrome) |
| Infusion time | Minimum 60 minutes per gram |
Condition-Specific Vancomycin Dosing
| Condition | Dose | Target Level |
|---|---|---|
| Sepsis / Bacteremia | 15-20 mg/kg IV q8-12h | AUC/MIC 400-600 mg·h/L |
| MRSA Pneumonia (HAP/VAP) | 15-20 mg/kg IV q8h (aggressive dosing - poor lung penetration) | Trough 15-20 mcg/mL |
| Meningitis / CNS | 15-20 mg/kg IV q8h (maximum dosing - poor CSF penetration) | Trough 15-20 mcg/mL |
| Endocarditis | 15 mg/kg IV q12h x 4-6 weeks | Trough 15-20 mcg/mL |
| Epidural Abscess | 30-60 mg/kg/day IV in 2 divided doses | AUC-guided |
| Febrile Neutropenia | 15 mg/kg IV q6-12h (adjust by renal function) | Trough 10-20 mcg/mL |
| Intraventricular (shunt infection) | 10-20 mg intraventricularlly once daily | CSF levels |
| Oral (C. diff only) | 125 mg PO QID (up to 500 mg QID severe) | Not monitored |
Vancomycin in Renal Impairment
| Renal Function | Dose Adjustment |
|---|---|
| CrCl 20-49 mL/min | 15 mg/kg q24h |
| CrCl 10-19 mL/min | 15 mg/kg q48h |
| Dialysis (non-high-flux) | 1 g (~15 mg/kg) every 5-7 days |
| High-flux dialysis | Supplemental dose after each dialysis session |
| Anuric / ESRD | Level-guided re-dosing |
Source: Goodman & Gilman's Pharmacological Basis of Therapeutics; Goodman & Gilman's 14th Ed.
Vancomycin Monitoring - Current Guidelines
- Old approach: Trough only - target 10-15 mcg/mL (general), 15-20 mcg/mL (serious MRSA)
- Current approach (2020 ASHP/IDSA/SIDP guidelines): Target AUC/MIC ratio of 400-600 mg·h/L using Bayesian estimation - more accurate, less nephrotoxic
- Levels drawn at steady state (before 4th dose)
CEFTAZIDIME - Standard Dosing
Adults (Normal Renal Function)
| Condition | Dose | Frequency |
|---|---|---|
| Pseudomonas bacteremia | 2 g IV | q8h |
| HAP/VAP (Pseudomonas cover) | 2 g IV | q8h |
| Meningitis / CNS infections | 2 g IV | q8h (some sources q4-6h for severe) |
| Febrile neutropenia | 2 g IV | q8h |
| Septic arthritis (Gram-neg rods) | 2 g IV | q8h |
| Epidural abscess / spinal osteomyelitis | 2 g IV | q8h (preferred when Pseudomonas suspected) |
| Urinary tract infection (severe) | 1-2 g IV | q8-12h |
| Intra-abdominal infection | 2 g IV | q8h |
Sources: Harrison's Internal Medicine 22E; Goldman-Cecil Medicine; Murray & Nadel Respiratory Medicine; Rosen's Emergency Medicine
Ceftazidime in Renal Impairment
| CrCl | Dose Adjustment |
|---|---|
| 31-50 mL/min | 1 g q12h |
| 16-30 mL/min | 1 g q24h |
| 6-15 mL/min | 500 mg q24h |
| <5 mL/min | 500 mg q48h |
| Hemodialysis | 1 g after each dialysis |
| Peritoneal dialysis | 500 mg q24h IP |
Combined Dosing by Clinical Scenario
| Condition | Vancomycin | Ceftazidime |
|---|---|---|
| Febrile neutropenia | 15 mg/kg IV q6-12h | 2 g IV q8h |
| HAP/VAP in ICU | 15-20 mg/kg IV q8-12h | 2 g IV q8h |
| Post-neurosurgery meningitis | 15-20 mg/kg IV q8h | 2 g IV q8h |
| CSF shunt infection | 15-20 mg/kg IV q8h | 2 g IV q8h |
| Epidural abscess | 30-60 mg/kg/day IV ÷ 2 doses | 2 g IV q8h |
| Sepsis (unknown source, ICU) | 25-30 mg/kg loading, then 15-20 mg/kg q8-12h | 2 g IV q8h |
| PD peritonitis (IP route) | Loading: 1000 mg IP, Maintenance: 25 mg/L per bag | 125-250 mg/L per bag IP |
Key Practical Points
- Always dose vancomycin by ACTUAL body weight (or adjusted body weight in obese patients - use with pharmacist input)
- Always get a renal function baseline (creatinine/eGFR) before starting both drugs - both are renally cleared
- Ceftazidime infusion: Give over 30 minutes IV; can use extended infusion (3-4 hours) for Pseudomonas to maximize time-dependent killing
- Vancomycin + ceftazidime = both nephrotoxic - monitor renal function every 48-72 hours and adjust doses accordingly
- De-escalate once culture results are available - if only Gram-positives, stop ceftazidime; if only Gram-negatives, stop vancomycin
This is a shared conversation. Sign in to Orris to start your own chat.